Loading…
Loading…
EQUITY / NASDAQ · XNCM
Lunai Bioworks Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →01/01/2026 – 03/31/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.3 USD · 0%
Observed: Oct 2, 2026, 8:00 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/02/2026 · 1.3 USD · Volume 124,995
21 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
01/01/2026 – 03/31/2026 · Units
| Metric | 2026 / Quarter 3 | 2025 / Quarter 3 | Change |
|---|---|---|---|
| Revenue | 20,942 USD | — | — |
| Operating profit | -1,477,260 USD | -4,162,492 USD | — |
| Net income | -2,571,394 USD | 189,176 USD | -1,459.26% |
| Cash and cash equivalents | 3,155,272 USD | — | — |
| Total liabilities | 19,413,968 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 301/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 307/01/2025 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 310/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2026 / Quarter 207/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2026 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 306/30/2025 – 06/30/2025ConsolidatedUnits · USD | 2025 / Year end07/01/2024 – 06/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 03/31/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 3,155,272 USD | — | — | — | — | 92,700 USD | 92,700 USD | — |
| Gross profitIncome statement | 20,942 USD | 20,942 USD | — | — | — | — | — | — |
| Net incomeIncome statement | -2,571,394 USD | -1,551,778 USD | -1,799,404 USD | 1,019,617 USD | 2,819,021 USD | — | -178,007,489 USD | 189,176 USD |
| Operating profitIncome statement | -1,477,260 USD | -6,559,034 USD | — | -5,131,774 USD | — | — | -188,966,002 USD | -4,162,492 USD |
| RevenueIncome statement | 20,942 USD | 20,942 USD | — | — | — | — | — | — |
| Total assetsBalance sheet | 9,860,540 USD | — | — | — | — | 8,230,840 USD | 8,230,840 USD | — |
| Total equityBalance sheet | -9,553,428 USD | — | -13,548,788 USD | — | -13,040,774 USD | -21,349,841 USD | -21,349,841 USD | 88,386,827 USD |
| Total liabilitiesBalance sheet | 19,413,968 USD | — | — | — | — | 29,580,681 USD | 29,580,681 USD | — |
| Capital expendituresCash flow statement | — | 1,238 USD | — | 1,238 USD | — | — | — | — |
| Financing cash flowCash flow statement | — | 5,996,869 USD | — | 2,293,357 USD | — | — | 8,382,772 USD | — |
| Investing cash flowCash flow statement | — | 543,462 USD | — | 543,462 USD | — | — | -500,000 USD | — |
| Operating cash flowCash flow statement | — | -3,447,179 USD | — | -2,420,323 USD | — | — | -7,874,647 USD | — |
| Report source | Open report ↗ Published: 05/15/2026 | Open report ↗ Published: 05/15/2026 | Open report ↗ Published: 05/15/2026 | Open report ↗ Published: 02/17/2026 | Open report ↗ Published: 05/15/2026 | Open report ↗ Published: 05/15/2026 | Open report ↗ Published: 09/29/2025 | Open report ↗ Published: 05/15/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.